![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Copyright © 2007, The Rockefeller University Press Article Spatial targeting of type II protein kinase A to filopodia mediates the regulation of growth cone guidance by cAMP Department of Neuroscience and Cell Biology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854 Correspondence to James Q. Zheng: zhengjq/at/umdnj.edu Received July 24, 2006; Accepted December 1, 2006. This article has been cited by other articles in PMC.Abstract The second messenger cyclic adenosine monophosphate (cAMP) plays a pivotal role in axonal growth and guidance, but its downstream mechanisms remain elusive. In this study, we report that type II protein kinase A (PKA) is highly enriched in growth cone filopodia, and this spatial localization enables the coupling of cAMP signaling to its specific effectors to regulate guidance responses. Disrupting the localization of PKA to filopodia impairs cAMP-mediated growth cone attraction and prevents the switching of repulsive responses to attraction by elevated cAMP. Our data further show that PKA targets protein phosphatase-1 (PP1) through the phosphorylation of a regulatory protein inhibitor-1 (I-1) to promote growth cone attraction. Finally, we find that I-1 and PP1 mediate growth cone repulsion induced by myelin-associated glycoprotein. These findings demonstrate that the spatial localization of type II PKA to growth cone filopodia plays an important role in the regulation of growth cone motility and guidance by cAMP. Introduction Guided axonal growth is essential for both the initial wiring of neuronal circuitry during development and the regeneration of synaptic connections in the adult nervous system after injury and diseases (Bahr and Bonhoeffer, 1994; Aubert et al., 1995; Tessier-Lavigne and Goodman, 1996; Harel and Strittmatter, 2006). The directional motility of the growth cone at axonal tips is regulated by a variety of environmental factors that either promote/attract or inhibit/repel the axonal elongation (Tessier-Lavigne and Goodman, 1996; Dickson, 2002). Although many families of guidance ligands and receptors have been recently identified (Tessier-Lavigne and Goodman, 1996; Dickson, 2002; Charron and Tessier-Lavigne, 2005), the intricate signaling cascades that control and regulate axonal growth and guidance remain to be fully understood. The second messenger, cAMP, represents an important intracellular signal that exhibits profound effects on growth cone motility and guidance. Previous studies have linked elevated cAMP signaling with enhanced elongation of growth cones (Richter-Landsberg and Jastorff, 1986; Rydel and Greene, 1988; Zheng et al., 1994b). The importance of cAMP regulation of axonal growth is further augmented by recent findings that manipulating the cAMP signaling pathway can overwrite the inhibitory/repulsive effects of some extracellular molecules on axonal growth, even converting them to attractive/positive responses (Song and Poo, 1999). For instance, an elevation of cAMP levels has been shown to convert myelin-associated glycoprotein (MAG)–induced growth cone repulsion to attraction in culture and promote axonal regeneration in vivo (Song et al., 1998; Qiu et al., 2002; Spencer and Filbin, 2004). Therefore, the cAMP pathway could be a potential target for therapeutic intervention to promote nerve regeneration after injury and degeneration (Filbin, 2003; Skaper, 2005). At present, the exact signaling mechanisms underlying cAMP effects on growth cones remain unclear. The existence of the intricate cross talk of cAMP to other signaling pathways has added more complexity to this issue. For example, both Ca2+ and cAMP are key second messengers involved in growth cone guidance by several extracellular cues, and Ca2+-dependent turning responses can be modulated by the cAMP pathway: the elevation of cAMP levels dictates attraction, whereas the inhibition of PKA results in repulsion (Song and Poo, 1999). It has been proposed that cAMP signaling could affect the Ca2+ signals elicited by extracellular cues through the modification of voltage-dependent Ca2+ channels or Ca2+ release from the intracellular Ca2+ stores (Nishiyama et al., 2003; Henley et al., 2004; Ooashi et al., 2005). Our recent work suggests that PKA targets a downstream component in the Ca2+ signaling pathway, protein phosphatase-1 (PP1), to allow the switching of repulsion to attraction (Wen et al., 2004). It is conceivable that cAMP could act at multiple steps in the Ca2+ signaling pathway to affect growth cone behaviors, but how it specifically targets distinct downstream effectors remains to be investigated. The cAMP molecule can diffuse over a long distance in the cytosol to activate a wide range of effectors (Kasai and Petersen, 1994), and its major effector, PKA, is a multifunctional enzyme with a broad substrate specificity (Shabb, 2001). Therefore, the mechanisms for spatiotemporal selectivity and efficiency in cAMP/PKA signaling are of particular interest. Between two major subtypes of PKA, type II PKA is often localized to subcellular compartments for coupling to specific downstream targets through a large family of AKAPs (a kinase-anchoring proteins; Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). Such spatial targeting of PKA to specific cellular locations and signaling partners through the interaction of PKA regulatory subunits with AKAPs (Hausken et al., 1994; Hausken and Scott, 1996) has been demonstrated to be crucial for many cellular functions (Carnegie and Scott, 2003; Tasken and Aandahl, 2004; for review see Wong and Scott, 2004), including PKA regulation of muscle contractibility (Ruehr et al., 2004) and synaptic plasticity (Bauman et al., 2004). Whether the spatial targeting of PKA is important for guidance signaling in growth cones is not clear. A recent study of axon guidance in Drosophila melanogaster suggests that the plexin A–binding protein Nervy functions as an AKAP to antagonize semaphorin 1A–plexin A-mediated repulsion by linking cAMP/PKA to plexin A receptor (Terman and Kolodkin, 2004). In the present study, we used cultured embryonic Xenopus laevis neurons to dissect the cAMP signaling mechanisms. We first investigated the subcellular distribution of the two major PKA subtypes in Xenopus growth cones and found that type II, not type I, PKA was highly enriched in filopodia. Disruption of the filopodial localization of type II PKA abolished cAMP effects on growth cone guidance. Next, we identified a PP1 regulatory protein, inhibitor-1 (I-1), as the target of PKA in cAMP regulation of growth cone turning responses to several guidance molecules. Furthermore, we observed a colocalization of type II PKA, I-1, and PP1 in growth cone filopodia, indicating that the spatial coupling of these signaling components is important for cAMP regulation of growth cone responses. Finally, we found that I-1 and PP1 mediated growth cone repulsion induced by MAG. These findings indicate that distinct subcellular localization of type II PKA represents an important mechanism for specific cAMP/PKA signaling in growth cone guidance. Results Localization of type II PKA to growth cone filopodia To examine the spatial distribution of two major PKA subtypes, type I and II, in Xenopus neurons, antibodies against their regulatory subunits (RI and RII) were used for immunofluorescent labeling. The reactivity and specificity of these antibodies to Xenopus tissues were confirmed by Western blotting (Fig. 1 A
To quantitatively demonstrate the filopodial enrichment of PKA RII, we measured the immunofluorescence intensity of RI and RII in three regions of the neuron: the filopodia, the growth cone (excluding filopodia), and the adjacent axonal shaft (see the schematic diagram in Fig. 1 H
The type II PKA is often targeted to subcellular domains by AKAPs (Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). Using a previously described PKA RII overlay approach (Williams, 2002), we found several bands from Xenopus neural tube tissues that were eliminated by Ht31 but not Ht31P peptides (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200607128/DC1). Ht31 encodes the PKA RII–binding sequence of a human thyroid AKAP (Carr et al., 1992) and is widely used for the competitive and specific disruption of PKA RII–AKAP binding, whereas Ht31P is the negative control derived from Ht31 with two amino acids mutated (Colledge and Scott, 1999). This result suggests the presence of AKAPs in Xenopus neurons. To directly test the role of AKAPs in PKA localization in Xenopus growth cones, we treated the neuronal culture with a membrane-permeable Ht31 peptide (stearated Ht31 [St-Ht31]) and found that the filopodial localization of RII was greatly reduced (Fig. 1 F PKA localization by AKAPs is required for cAMP regulation of growth cone guidance Because filopodia are involved in directional responses of growth cones to guidance cues (Chien et al., 1993; Kater and Rehder, 1995; Zheng et al., 1996; Gomez et al., 2001), the localization of type II PKA in filopodia suggests a potential role in growth cone guidance. To test this notion, growth cone turning assays were performed in which a guidance gradient was established by pulsatile pressure ejection of a guidance solution from a micropipette (Lohof et al., 1992; Zheng et al., 1994a). Relatively large and motile growth cones of cultured Xenopus spinal neurons on laminin were used for assessing turning responses to several extracellular gradients (Guirland et al., 2003; Wen et al., 2004). We first examined growth cone attraction induced by a gradient of membrane-permeant cAMP analogues (Lohof et al., 1992; Guirland et al., 2003). A Sp-cAMPS gradient (20 mM in the ejection pipette and ~20 μM reaching the growth cone) induced a marked attraction of Xenopus growth cones within 30 min (Fig. 2 A
We also examined growth cone attraction induced by a gradient of pituitary adenylate cyclase–activating polypeptide (PACAP), a neuropeptide that is known to activate G protein–coupled receptors to elevate cytosolic cAMP levels (Vaudry et al., 2000). As we reported previously (Guirland et al., 2003), a PACAP gradient (1 μM in the pipette and ~1 nM at the growth cone) induced a marked attraction of Xenopus growth cones (Fig. 2 D One profound effect of the cAMP pathway on Ca2+-dependent growth cone guidance is to switch repulsion to attraction through PKA activation or vice versa (Song and Poo, 1999). We examined the role of type II PKA and its spatial localization in the switching of turning responses. Xenopus growth cones plated on the laminin surface exhibited an attractive response to a gradient of brain-derived neurotrophic factor (BDNF; 50 μg/ml in the pipette and ~50 ng/ml at the growth cone), which could be converted to repulsion by PKA inhibition through the bath application of 20 μM Rp-cAMPS (Fig. 3
We next examined growth cone repulsion in response to a gradient of MAG, a key inhibitory molecule in axon regeneration after injury in the central nervous system (Filbin, 2003). In our Xenopus cultures, a gradient of MAG effectively induced the repulsive turning of most growth cones to result in a negative average turning angle (Fig. 3 I-1 is the downstream target of type II PKA signaling in growth cone turning Localization of PKA via AKAPs is thought to couple PKA activity to specific downstream targets, a mechanism that is believed to control cAMP spatiotemporal signaling in the cell (Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). Our previous study suggests that PKA regulates Ca2+-dependent growth cone turning through the inhibition of PP1 (Wen et al., 2004). PP1 activity is known to be regulated by a regulatory protein, I-1, whose phosphorylation by PKA at Thr35 leads to PP1 inhibition, and dephosphorylation by calcineurin (CaN) relieves the inhibition (Ceulemans and Bollen, 2004). Because PP1 inhibition appears to be important for cAMP switching of Ca2+-dependent repulsion to attraction (Wen et al., 2004), we tested whether I-1 is a key substrate for spatially localized type II PKA in guidance regulation. Because our Xenopus cultures typically contain a large population of myocytes, we used rat hippocampal cultures for biochemical analysis of I-1 phosphorylation and its dependence on AKAPs. At first, we performed immunofluorescent staining and found that PKA RII was also enriched in the growth cone filopodia of cultured hippocampal neurons (2–3 d in vitro; Fig. 4 A We next examined the distribution of I-1 in Xenopus growth cones and its role in guidance. Similar to hippocampal neurons, I-1 was found to be concentrated in filopodia and colocalized with PKA RII (Fig. 5 A
PP1 inhibition is a key event downstream of PKA activation for guidance regulation Many AKAPs not only bind PKA holoenzymes but also recruit other molecules to create signaling complexes, which is believed to be important for signal integration as well as for the efficiency and specificity of PKA activity (Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). We hypothesized that PKA inhibition of PP1 through I-1 may also involve a similar mechanism to regulate growth cone responses to guidance molecules. We first performed coimmunoprecipitation (co-IP) using Xenopus neural tube tissues to examine whether type II PKA and PP1 were present in a signaling complex. Using specific antibodies against PKA RII and PP1γ, we found that a small amount of PP1γ could be consistently pulled down by RII (but not by RI) and vice versa (Fig. 6 A
To further test the model that PKA exerts its regulation on growth cone turning primarily through the inhibition of PP1, we used the turning assay to examine the effects of the direct inhibition of PP1 using specific inhibitors. We first tested the notion that growth cone attraction induced by a gradient of cAMP involves a local (asymmetric) inhibition of PP1. Here, a gradient of the PP1 inhibitor tautomycin was generated by pulsatile ejection of 3 μM tautomycin solution from the pipette (estimated ~3 nM at the growth cone). We found that asymmetric inhibition of PP1 by the tautomycin gradient elicited a marked attractive turning of Xenopus growth cones (Fig. 6 C I-1 and PP1 mediate MAG-induced growth cone repulsion MAG is a key inhibitory molecule in axon regeneration in the central nervous system (Filbin, 2003). MAG-induced growth cone repulsion has been shown to involve Ca2+ and can be switched to attraction by cAMP (Song et al., 1998; Henley et al., 2004). In our Xenopus cultures, a gradient of MAG consistently induced growth cone repulsion, and the repulsion could be converted to attraction by the bath application of Sp-cAMPS (Fig. 7 A
Discussion The major cAMP pathway is believed to involve the activation of PKA, which, in turn, phosphorylates a variety of downstream substrates for distinct signaling cascades. It is interesting to note that cAMP molecules can diffuse over long distances in the cytosol (Kasai and Petersen, 1994), and PKA does not possess a high degree of substrate selectivity (Shabb, 2001). Thus, the target specificity and phosphorylation efficiency of PKA in a distinct signaling pathway are believed to involve spatial coupling of PKA to its appropriate downstream effectors through a large family of AKAPs (Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). It has been shown that type II PKA is the major subtype that associates with AKAPs and often exhibits localized subcellular distribution (Tasken and Aandahl, 2004; for review see Wong and Scott, 2004). In the present study, we present evidence that spatially distributed type II PKA is involved in growth cone guidance. The striking localization of type II PKA in growth cone filopodia indicates that it may be involved in regulation of the actin cytoskeleton dynamics underlying growth cone motility and guidance. Using the turning assay, we have provided direct evidence that the spatial localization of type II PKA in filopodia is required for cAMP-induced growth cone turning and switching of turning responses to guidance gradients. Furthermore, we have obtained evidence that PKA acts on PP1 through I-1 (all localized in filopodia) to regulate growth cone turning responses. These findings indicate an exciting model in which spatial targeting of PKA to its downstream targets in growth cone filopodia allows the profound cAMP regulation of growth cone responses to guidance cues. There is a large body of studies demonstrating that AKAPs are the major family of scaffolding proteins for the subcellular localization of PKA molecules (for review see Wong and Scott, 2004). The predominant localization of type II PKA in growth cone filopodia is likely mediated by AKAPs because it was diminished by the inhibitory peptide St-Ht31 (Fig. 1
Another interesting observation came from the immunostaining experiment in which anti-RII antibodies were premixed with recombinant RII proteins (Fig. 1 E The second major finding of this study is that the PKA inhibition of PP1 through I-1 acts as a key mechanism underlying cAMP regulation of growth cone guidance. Our previous work has shown that local activation of the CaN–PP1 pathway by Ca2+ signals induces repulsion, and cAMP activation of PKA inhibits the CaN–PP1 repulsive pathway to allow the conversion of repulsion to attraction (Wen et al., 2004). In this study, we provided evidence that I-1 is a target of PKA and CaN that oppositely controls PP1 activity for distinct turning responses (Fig. 9
MAG is an important component of inhibitory molecules in central nervous system axon regeneration, and one important insight into MAG signaling came from the observation that MAG-induced repulsion was blocked by I-1 knockdown. A previous study indicates that MAG-induced repulsive turning involves small local Ca2+ elevations (Henley et al., 2004), which likely act through CaN–PP1 (Wen et al., 2004). Because CaN dephosphorylates I-1 at Thr35 (Thr34 for Xenopus) to remove its inhibition on PP1, the local Ca2+ activation of CaN would lead to the local elevation of PP1 activity for repulsive turning. The fact that the direct inhibition of PP1 was able to convert the MAG effect to attraction provides direct support for Ca2+-CaN–PP1 in MAG signaling during repulsion. Morpholino knockdown of I-1 disrupts the signaling transduction from CaN to PP1, thus resulting in the blockade of repulsion. However, unlike PP1 inhibition or PKA activation, I-1 knockdown did not convert MAG-induced repulsion to attraction but instead abolished turning responses. Previous studies have indicated that a spatial balance of Ca-calmodulin–dependent kinase II (CaMKII) and PP1 activities control the bidirectional steering of the growth cones (Fig. 9 A Increasing evidence indicates that the spatiotemporal control of cascades of signaling reactions in confined subcellular locations is key for intricate signal transduction occurring in the living cells. This study has established that spatial targeting of PKA to filopodia allows the signal transduction through cAMP, type II PKA, I-1, and PP1 to regulate growth cone turning. Given the apparent localization of PKA RII, I-1, and some PP1 in filopodia, it is conceivable that interactions between type II PKA and PP1 may affect the activity of molecules that regulate the actin cytoskeleton and/or membrane-substrate adhesion. For instance, PP1 is found to directly dephosphorylate actin-depolymerizing factor/cofilin (Meberg et al., 1998), thereby promoting actin depolymerization. It is also possible that PP1 may modulate Ca2+ signals through the negative regulation of Ca2+ channels and stores (Ceulemans and Bollen, 2004) to influence Ca2+-dependent guidance. Our study has also provided additional support for the model that a spatial balance of CaMKII and CaN–PP1 activity controls bidirectional steering of the growth cone (Fig. 9 A Materials and methods Antibodies and reagents Antibodies against different antigens used in this study are as follows: PKA RIIβ (BD Biosciences); PKA RII and RI, PP1, and PP1γ (Santa Cruz Biotechnology, Inc.); I-1/DARPP-32 (Chemicon); and phospho–I-1/DARPP-32 (Novus Biologicals). Recombinant rat MAG-Fc was purchased from R&D Systems, and recombinant human BDNF was provided by Regeneron. PACAP was obtained from American Peptide. PKA RII proteins were provided by the laboratory of S. Taylor (University of California, San Diego, La Jolla, CA) as well as purchased from Biaffin GmbH and Co KG. St-Ht31 and St-Ht31P were purchased from Promega. Cyclic nucleotides (Sp-cAMPS, Rp-cAMPS, Sp-cGMPS, and Rp-cGMPS), tautomycin, deltamethrin, OA, and forskolin were all obtained from Calbiochem. A morpholino antisense oligonucleotide specific for I-1 was designed and synthesized by Gene Tools, LLC, with the sequence 5′-ATGGAGGCGAACAGTCCCAGGAAGA-3′. A control morpholino was used with the sequence 5′-CCTCTTACCTCAGTTACAATTTATA-3′. Cell cultures and embryo microinjection Embryonic cultures of Xenopus spinal neurons were prepared from neural tube tissues of stage 20–22 embryos and plated on coverslips coated with poly-d-lysine and laminin (Sigma-Aldrich) in a serum-free medium as described previously (Guirland et al., 2003). The serum-free medium consisted of 50% (vol/vol) Leibovitz L-15 medium (Sigma-Aldrich), 50% (vol/vol) Ringer's solution (115 mM NaCl, 2 mM CaCl2, 2.5 mM KCl, and 10 mM Hepes, pH 7.6), and 1% (wt/vol) BSA (Sigma-Aldrich). Xenopus cultures were maintained at 20–22°C for 6–10 h before fixation or were used for the turning assay. In I-1 knockdown experiments, I-1 or control morpholino oligonucleotides together with a fixable Oregon green–dextran conjugate (Invitrogen) were injected into the animal pole of one-cell Xenopus embryos (Alder et al., 1995). The injected embryos were screened 24 h later for the presence of fluorescence and were used for cell culture. For turning assays, the cells exhibiting the green fluorescence of Oregon green–dextran were used. Primary hippocampal neurons were prepared from embryonic day 18 rat embryos (Banker and Cowan, 1977), plated on coverslips or into culture dishes coated with poly-d-lysine at a density of ~600,000 cells/ml (for Western blotting) or ~100,000 cells/ml (for immunofluorescence), and incubated at 37°C with 5% CO2 in MEM supplemented with 10% FBS (Invitrogen), 0.5% glucose, 1 mM sodium pyruvate, 25 μM glutamine, and 1× penicillin-streptomycin. The next day after plating, the medium was changed to the Neurobasal medium (Invitrogen) supplemented with 1× B27 supplement (Invitrogen). For immunofluorescence experiments, neurons were fixed after 2–3 d in vitro. For Western blotting, neurons were first treated with different drugs on day in vitro 5 and then were lysed in radioimmunoprecipitation buffer (50 mM Tris, 50 mM NaF, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 0.4 mM Na3VO4, 1 mM PMSF, 1 mg/ml leupeptin, 5 mg/ml chymostatin, 1 mg/ml pepstatin, and 5 mM E64). All studies involving vertebrate animals (frogs and rats) are performed in accordance with the National Institutes of Health (NIH) guidelines and were approved by the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey. Immunofluorescence and quantification of fluorescence intensity Cells on coverslips were fixed with 4% PFA in a cacodylate buffer (Guirland et al., 2003) for 30 min at room temperature and were permeabilized with 0.5% Triton X-100 for 10 min. Samples were blocked overnight in 10% BSA in PBS followed by sequential incubation with primary and secondary antibodies. Coverslips were mounted on slides and visualized through a 60× NA 1.4 plan Fluor oil immersion objective (Nikon) on an inverted epifluorescence microscope (TE2000; Nikon) equipped with a CCD camera (SensiCam QE; Cooke Scientific). Fluorescence images were taken using IPLab software (version 3.7; BD Biosciences) and transferred to ImageJ software (NIH) for fluorescence intensity measurement and color coding and merging. The settings for imaging and processing were fixed throughout the experiments. Quantification of the fluorescence intensity was performed by first subtracting the background and then measuring the average intensity from the regions of interest that were hand traced using ImageJ. For the axonal shaft, we simply placed an oval region in the shaft for measurement of the intensity. Measurements from each growth cone were normalized, and results from multiple growth cones were then averaged. Immunoprecipitation and Western blotting Xenopus neural tube tissues were lysed in the radioimmunoprecipitation buffer, and the clarified lysates were incubated with antibodies against RII (with or without St-Ht31), RI, PP1γ, or normal IgG (Santa Cruz Biotechnology, Inc.) overnight at 4°C. Immune complexes were isolated by incubation with protein A/G PLUS agarose (Santa Cruz Biotechnology, Inc.) for 2 h at 4°C. Cell lysates or IP samples were separated on NuPAGE Novex 3–8% Tris-acetate gels (Invitrogen) or 10% Tris-glycine gels and were transferred to nitrocellulose membranes. After incubation with appropriate primary antibodies, the membranes were detected by HRP-conjugated secondary antibodies and ECL reagents (GE Healthcare). Growth cone turning induced by extracellular chemical gradients Growth cone turning induced by chemical gradients was performed with a modified Ringer's solution (115 mM NaCl, 2.6 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM Hepes, pH 7.6) as described previously (Ming et al., 1999; Guirland et al., 2004). Microscopic gradients of chemicals were produced by repetitive pressure ejection through a micropipette with an opening of 1 μm (pressure of 3 pounds per square inch, repetition of 2 Hz, and duration of 20 ms). Under these settings, the concentration of the chemical reaching the growth cone is estimated to be ~1/1,000th of that in the pipette (Lohof et al., 1992; Zheng et al., 1994a). The original direction of growth cone extension at the beginning of the experiment was defined by the distal 20-μm segment of the neurite. The pipette tip was positioned 45° from the initial direction of extension and 100 μm away from the growth cone. Different reagents were added to the bath medium 20 min before the onset of turning assays. To quantify the turning responses, digital images of the growth cone at the onset and end of the 30-min turning assay were acquired and overlaid with pixel-to-pixel accuracy, and the trajectory of new neurite extension was traced using Photoshop (Adobe). The turning angle was defined by the angle between the original direction of neurite extension and a line connecting the positions of the growth cone at the onset and end of the experiment. A positive angle resulted from turning toward the pipette and vice versa. Neurite extension was quantified by measuring the trajectory of net neurite extension over the 30-min period. Only growth cones that extended 5 μm or more were scored and analyzed for turning responses. We used the nonparametric Mann-Whitney test to analyze turning angles (expressed as mean ± SEM) because they do not follow a normal distribution. Online supplemental material Fig. S1 shows the filopodia localization of PKA RII in cultured hippocampal neurons. Fig. S2 shows the existence of potential AKAPs in Xenopus neural tube tissues through an RII overlay assay. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200607128/DC1. Acknowledgments We would like to thank Dr. Renping Zhou (Rutgers University, Piscataway, NJ) for his help on this project and Dr. Susan Taylor for providing recombinant PKA RII proteins. This research is supported by grants from NIH (NS036241) and the New Jersey Commission on Spinal Cord Research (NJCSCR; 04-3029-SCR) to J.Q. Zheng as well as a postdoctoral fellowship from NJCSCR to J. Han (grant 06-2918-SCR). Notes Abbreviations used in this paper: AKAP, a kinase-anchoring protein; BDNF, brain-derived neurotrophic factor; CaMKII, Ca-calmodulin–dependent kinase II; CaN, calcineurin; CM, control morpholino; DARPP-32, dopamine- and cAMP-regulated phosphoprotein of 32 kD; I-1, inhibitor-1; IM, I-1 morpholino; IP, immunoprecipitation; MAG, myelin-associated glycoprotein; NT-3, neurotrophin-3; OA, okadaic acid; PACAP, pituitary adenylate cyclase–activating polypeptide; PP1, protein phosphatase-1. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
Trends Neurosci. 1994 Nov; 17(11):473-9.
[Trends Neurosci. 1994]Curr Opin Neurobiol. 1995 Oct; 5(5):625-35.
[Curr Opin Neurobiol. 1995]Science. 1996 Nov 15; 274(5290):1123-33.
[Science. 1996]Nat Rev Neurosci. 2006 Aug; 7(8):603-16.
[Nat Rev Neurosci. 2006]Science. 2002 Dec 6; 298(5600):1959-64.
[Science. 2002]Curr Opin Neurobiol. 1999 Jun; 9(3):355-63.
[Curr Opin Neurobiol. 1999]Nature. 2003 Jun 26; 423(6943):990-5.
[Nature. 2003]Neuron. 2004 Dec 16; 44(6):909-16.
[Neuron. 2004]J Cell Biol. 2005 Sep 26; 170(7):1159-67.
[J Cell Biol. 2005]Neuron. 2004 Sep 16; 43(6):835-46.
[Neuron. 2004]Trends Neurosci. 1994 Mar; 17(3):95-101.
[Trends Neurosci. 1994]Chem Rev. 2001 Aug; 101(8):2381-411.
[Chem Rev. 2001]Physiol Rev. 2004 Jan; 84(1):137-67.
[Physiol Rev. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]J Biol Chem. 1994 Sep 30; 269(39):24245-51.
[J Biol Chem. 1994]Physiol Rev. 2004 Jan; 84(1):137-67.
[Physiol Rev. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]J Immunol. 2002 Jun 1; 168(11):5392-6.
[J Immunol. 2002]J Biol Chem. 1992 Jul 5; 267(19):13376-82.
[J Biol Chem. 1992]Trends Cell Biol. 1999 Jun; 9(6):216-21.
[Trends Cell Biol. 1999]Neuron. 1993 Aug; 11(2):237-51.
[Neuron. 1993]Curr Opin Neurobiol. 1995 Feb; 5(1):68-74.
[Curr Opin Neurobiol. 1995]J Neurosci. 1996 Feb 1; 16(3):1140-9.
[J Neurosci. 1996]Science. 2001 Mar 9; 291(5510):1983-7.
[Science. 2001]J Neurosci. 1992 Apr; 12(4):1253-61.
[J Neurosci. 1992]Pharmacol Rev. 2000 Jun; 52(2):269-324.
[Pharmacol Rev. 2000]J Neurosci. 2003 Mar 15; 23(6):2274-83.
[J Neurosci. 2003]Curr Opin Neurobiol. 1995 Oct; 5(5):625-35.
[Curr Opin Neurobiol. 1995]Science. 1998 Sep 4; 281(5382):1515-8.
[Science. 1998]Curr Opin Neurobiol. 1999 Jun; 9(3):355-63.
[Curr Opin Neurobiol. 1999]Curr Opin Neurobiol. 1999 Jun; 9(3):355-63.
[Curr Opin Neurobiol. 1999]Nature. 1997 Jul 17; 388(6639):275-9.
[Nature. 1997]Neuron. 2004 Apr 8; 42(1):51-62.
[Neuron. 2004]Nat Rev Neurosci. 2003 Sep; 4(9):703-13.
[Nat Rev Neurosci. 2003]Science. 1998 Sep 4; 281(5382):1515-8.
[Science. 1998]Curr Opin Neurobiol. 1999 Jun; 9(3):355-63.
[Curr Opin Neurobiol. 1999]Physiol Rev. 2004 Jan; 84(1):137-67.
[Physiol Rev. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]Neuron. 2004 Sep 16; 43(6):835-46.
[Neuron. 2004]Physiol Rev. 2004 Jan; 84(1):1-39.
[Physiol Rev. 2004]Physiol Rev. 2004 Jan; 84(1):137-67.
[Physiol Rev. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]Nat Rev Neurosci. 2003 Sep; 4(9):703-13.
[Nat Rev Neurosci. 2003]Science. 1998 Sep 4; 281(5382):1515-8.
[Science. 1998]Neuron. 2004 Dec 16; 44(6):909-16.
[Neuron. 2004]Trends Neurosci. 1994 Mar; 17(3):95-101.
[Trends Neurosci. 1994]Chem Rev. 2001 Aug; 101(8):2381-411.
[Chem Rev. 2001]Physiol Rev. 2004 Jan; 84(1):137-67.
[Physiol Rev. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]Methods Mol Biol. 1998; 88():47-64.
[Methods Mol Biol. 1998]J Mol Cell Cardiol. 2004 Sep; 37(3):653-65.
[J Mol Cell Cardiol. 2004]Nat Rev Mol Cell Biol. 2004 Dec; 5(12):959-70.
[Nat Rev Mol Cell Biol. 2004]Proc Natl Acad Sci U S A. 2005 Oct 4; 102(40):14320-5.
[Proc Natl Acad Sci U S A. 2005]Neuron. 2004 Sep 16; 43(6):835-46.
[Neuron. 2004]J Neurosci. 1986 May; 6(5):1469-81.
[J Neurosci. 1986]J Cell Sci. 2005 Jun 1; 118(Pt 11):2485-94.
[J Cell Sci. 2005]Neuron. 2004 Sep 16; 43(6):835-46.
[Neuron. 2004]Neuron. 2004 Dec 16; 44(6):909-16.
[Neuron. 2004]Neuron. 2004 Sep 16; 43(6):835-46.
[Neuron. 2004]Nat Rev Neurosci. 2006 Feb; 7(2):115-25.
[Nat Rev Neurosci. 2006]Science. 1998 Jun 19; 280(5371):1940-2.
[Science. 1998]J Neurosci. 2004 Sep 29; 24(39):8404-9.
[J Neurosci. 2004]Cell Motil Cytoskeleton. 1998; 39(2):172-90.
[Cell Motil Cytoskeleton. 1998]Physiol Rev. 2004 Jan; 84(1):1-39.
[Physiol Rev. 2004]J Neurosci. 2003 Mar 15; 23(6):2274-83.
[J Neurosci. 2003]J Neurosci. 1995 Jan; 15(1 Pt 2):511-9.
[J Neurosci. 1995]Brain Res. 1977 May 13; 126(3):397-42.
[Brain Res. 1977]J Neurosci. 2003 Mar 15; 23(6):2274-83.
[J Neurosci. 2003]Neuron. 1999 May; 23(1):139-48.
[Neuron. 1999]Neuron. 2004 Apr 8; 42(1):51-62.
[Neuron. 2004]J Neurosci. 1992 Apr; 12(4):1253-61.
[J Neurosci. 1992]Nature. 1994 Mar 10; 368(6467):140-4.
[Nature. 1994]